Filing identity and reporting period
Important mismatch: The request identifies Tenax Therapeutics and 2011 Q2, but the supplied filing is Oxygen Biotherapeutics, Inc.’s Form 10-Q for the quarter ended October 31, 2012 (fiscal 2013 second quarter), filed December 14, 2012. The summary below reflects the supplied filing, not the requested company or period.
Oxygen Biotherapeutics describes itself as a development-stage biomedical company developing oxygen-carrying products. Its commercial product revenue came from Dermacyte; research grant revenue was primarily tied to U.S. Army-funded studies.
Financial performance
| Metric | Three months ended October 31, 2012 | Prior-year quarter | Six months ended October 31, 2012 | Prior-year six months |
|---|---|---|---|---|
| Total net revenue | $514,872 | $95,159 | $786,968 | $120,032 |
| Product revenue | $14,571 | $27,415 | $26,028 | $86,892 |
| Government grant revenue | $509,435 | $78,244 | $775,984 | $78,244 |
| Net loss | $1,557,278 | $2,929,923 | $5,143,819 | $5,798,992 |
| Net loss per share, basic | $0.05 loss | $0.12 loss | $0.17 loss | $0.25 loss |
Quarterly product gross profit was $5,437, or 37% of product revenue, versus $16,915, or 62%, a year earlier. Six-month product gross profit was $10,984, or 42%, versus $41,788, or 48%. The filing reports quarterly operating loss of approximately $0.7 million versus $2.1 million in the prior-year quarter.
For the six months, net cash used in operating activities was $2.74 million, investing activities used $70,781, and financing activities provided $2.44 million. Cash declined by $368,359 from April 30 to $1.51 million at October 31. Management separately reported quarterly operating cash use of approximately $1.1 million versus $2.5 million a year earlier.
At October 31, current assets were $2.12 million and current liabilities were $1.35 million, yielding working capital of $771,633. Total assets were $3.54 million; total liabilities were $3.60 million; stockholders’ deficit was $58,031. Notes payable had a net carrying value of $2.18 million long term and $7,195 current; the underlying convertible notes had $4.9 million principal and a 15% annual interest rate.
Material changes and operating developments
- Grant revenue rose sharply as funded studies progressed and grant milestones were achieved. Product revenue fell 47% in the quarter and 70% for six months, which management attributed to a smaller sales force and discontinued distribution arrangements.
- Six-month interest expense more than doubled to $2.79 million, including convertible-note discount amortization and non-cash preferred-stock-related charges.
- The company recorded $217,774 of restructuring expense after closing its California R&D facility, relocating the R&D function to North Carolina, ending internal manufacturing and development activities, and moving manufacturing to contract manufacturers. It recorded a $363,691 long-lived asset impairment for the period from inception, but the filing’s specific current-period discussion identifies approximately $12,000 related to lab equipment disposal.
- During the quarter, the company reported completing Oxycyte preclinical pharmacokinetics studies, completing in-vitro platelet-function studies in healthy volunteers, beginning repeat studies using TBI subjects, starting preclinical immune-system studies, and engaging a CRO for Phase II-B traumatic brain injury trials. Enrollment was expected to resume in the next fiscal quarter.
- In the six-month period, 3,281 preferred shares were converted into 3,132,017 common shares. Common shares outstanding increased to 32,899,900 at October 31; the filing reported 33,133,895 outstanding at December 12.
Outlook, risks and contingencies
- Going concern and financing: The filing states substantial doubt exists about the company’s ability to continue as a going concern. Management estimated cash would fund operations only through January 31, 2013 and said further product development depends on additional financing, licensing income or other outside resources. No assurance was given that funding would be available.
- The final potential $1.5 million closing under the preferred-stock financing did not occur because the stock price was below the required minimum. The preferred securities carry a 7% dividend and scheduled redemption/amortization features; certain triggering events can require cash redemption at a premium. The company expected to make scheduled payments in common stock when permitted.
- NASDAQ listing: The company received deficiency notices for market capitalization below $35 million and share price below $1.00. It had until March 19, 2013 and April 1, 2013, respectively, to regain compliance; delisting could reduce liquidity and impair future fundraising.
- Litigation: A court found the company breached Tenor investors’ right-of-first-offer agreement in connection with a 2011 financing. A jury trial to determine damages was scheduled for March 7, 2013. The company had not accrued a liability, stating it believed damages were unsupported; the filing warns a significant award could harm its financial condition and going-concern prospects.
- Other disclosed risks include clinical and regulatory uncertainty, the need for substantial development funding, potential dilution from equity financing, and the possibility that debt or partnering terms could be restrictive or unfavorable. Management provided no quantified financial forecast beyond its cash-runway estimate.
Investor verification priorities
- Confirm that this Oxygen Biotherapeutics filing—not a Tenax Therapeutics filing—is the intended document and period.
- Review subsequent financing, cash burn, and whether operations continued beyond the stated January 31, 2013 runway.
- Check the outcome and any financial impact of the Tenor damages trial and the NASDAQ listing deficiencies.
- Verify Oxycyte Phase II-B trial restart, enrollment, and subsequent clinical and regulatory developments.
- Assess preferred-stock conversion/redemption terms, dilution, and the 15% convertible-note obligations.